Lack of complete response pretransplant is not associated with inferior overall survival for stage 4a metastatic retinoblastoma Journal Article

   

Authors:	Sait, S. F.; Bernot, M. R.; Klein, E.; Abramson, D. H.; Francis, J. H.; Gilheeney, S.; Karajannis, M. A.; Spitzer, B.; Wolden, S.; Dunkel, I. J.; Kernan, N. A.
Article Title:	Lack of complete response pretransplant is not associated with inferior overall survival for stage 4a metastatic retinoblastoma
Abstract:	Background Stage 4a metastatic retinoblastoma (RB) is curable with intensive multimodality therapy including myeloablative chemotherapy with autologous stem cell transplant (HDC-ASCT) and involved field radiation therapy (IFRT). To our knowledge, no data exist on the impact of (a) pre-ASCT disease status, and (b) IFRT to sites of metastatic disease post ASCT on survival. Procedure We retrospectively reviewed patients with stage 4a metastatic RB who underwent induction chemotherapy followed by HDC-ASCT, with or without IFRT, to residual tumor sites at Memorial Sloan Kettering Cancer Center (MSKCC) (n = 24). Results The degree of postinduction response prior to ASCT did not affect outcome, with 5-year overall survival (OS) of 68% and 86% in patients who achieved complete response (CR) and very good partial response (VGPR)/partial response (PR) prior to ASCT, respectively. IFRT administered post ASCT in patients with possible residual bony metastatic disease increases the likelihood of developing osteosarcoma in the radiation field. Conclusion OS for patients with stage 4a metastatic RB treated with ASCT with VGPR or PR to pretransplant chemotherapy was not significantly different from patients with CR. In addition, IFRT does not seem to be required for bony disease control and increased the likelihood of developing osteosarcoma.
Keywords:	carboplatin; retinoblastoma; risk; tumors; radiation therapy; children; metastatic; transplant; high-dose chemotherapy; stem-cell rescue; extraocular retinoblastoma
Journal Title:	Pediatric Blood and Cancer
Volume:	70
Issue:	1
ISSN:	1545-5009
Publisher:	Wiley Periodicals, Inc
Date Published:	2023-01-01
Start Page:	e29921
Language:	English
ACCESSION:	WOS:000837177800001
DOI:	10.1002/pbc.29921
PROVIDER:	wos
PUBMED:	35934994
PMCID:	PMC9701149
Notes:	Article -- e29921 -- MSK Core Grant P30 CA008748 mentioned in PubMed and PDF -- Corresponding author is MSK author Sameer Farouk Sait -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/201098